Though bevacizumab plus atezolizumab was an approved first-line therapy for advanced HCC, due to the patient's recent major gastrointestinal bleeding event, an inhibitor of programmed cell death protein 1 (PD-1) nivolumab, which was an alternative first-line therapy at the time, was promptly started at 480 mg per dose on a monthly basis. Here, PDCD1 is linked to hepatocellular carcinoma.